About us

APIM Therapeutics AS is a venture-capital financed biotech spin-off from the Norwegian University of Science and Technology (NTNU, Trondheim).

Based on an original discovery by Prof. Marit Otterlei and co-inventors, the company targets a novel therapeutic intervention point shown to be critical in the regulation of cellular responses to stress and in tumor evasion from therapy.

about us inner img

Briefly, APIM Therapeutics is using a series of proprietary Protein Protein Interaction (PPI) blocking peptides targeting complexes formed between PCNA (Proliferating Cell Nuclear Antigen) and proteins bearing a novel PCNA-interacting Peptide Motif called APIM (AlkB homolog 2 PCNA Interacting Motif). A series of preclinical and other experiments have revealed the functional importance of PCNA/APIM-protein interactions in the regulation of cancer cell growth and apoptosis during stress (e.g. DNA Damage Response) induced by anti-cancer treatment. Furthermore, it was shown that cell penetrating peptides containing the APIM-motif abrogate PCNA-APIM protein interactions and are capable of potentiating the action of several classes of anti-cancer drugs across multiple indications.

APIM’s lead therapeutic candidate ATX-101, is a first-in class compound targeting this therapeutic intervention point. In preclinical experiments, ATX-101 has shown single agent activity in certain cancers and combinatorial activity with more than 25 different anti-cancer drugs in different tumor indications. Developed as a new therapeutic option in oncology, ATX-101 has recently concluded a first-in-human, phase I clinical study. Conducted by APIM’s Australian subsidiary Therapim Pty Ltd, the study demonstrated a favorable safety profile of the compound. Furthermore, promising disease stabilization was observed in patients with advanced, progressive tumors lacking standard treatment options. The results of the phase I study have been published in Oncogene, see Publications for more details.  

Currently, ATX-101 is being tested in two clinical studies:

1. A phase Ib/IIa study in platinum-sensitive ovarian cancer conducted in Australia/APAC, testing ATX-101 in combination with platinum-based chemotherapy.

2. A phase II study in sarcoma (lipo-, and leiomyosarcoma) conducted as an Investigator Initiated Study by the Columbia University Irving Medical Center, evaluating ATX-101 as monotherapy

For more information on our technology, please see Intervention Point, ATX-101 and Publications.